Insulin-like growth factors and bone: The osteoporosis connection revisited

Proceedings of the Society for Experimental Biology and Medicine

Volumn 219, Issue 1, 1998, Pages 1-7

  Rosen, Clifford J ^a   Donahue, Leah Rae ^b  

^a ST JOSEPH HOSPITAL   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

BONE GROWTH; BONE MASS; GROWTH REGULATION; HUMAN; OSTEOPOROSIS; PATHOGENESIS; PATHOLOGIC FRACTURE; SHORT SURVEY;

EID: 0031693595     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-219-44310     Document Type: Short Survey

References (57)

1. Jones J, Clemmons DR. IGFs and their binding proteins. Endocr Rev 16:3-32, 1995.
2. LeRoith D, Parrizas M, Blakesley VA. IGF-I receptor and apoptosis. Endocrine 7:103-105, 1997.
3. Mohan S, Baylink DJ, Eds. Characterization of the IGF regulatory system in bone. In: LeRoith D, Raizada MK, Eds. Current Directions in Insulin-Like Growth Factor Research. New York: Plenum Press, 397-406, 1994.
4. Mohan S, Baylink DJ. Autocrine and paracrine aspects of bone metabolism. Growth, Genetics and Hormones 6:1-9, 1990.
5. Nicholas V, Prewett A, Beltica P, Mohan S, Finkelman R, Baylink DJ, Farley AJ. Age-related declines in IGF-I and TGF-β in femoral cortical bone from men and women. J Clin Endocrinol Metab 78:1011-1016, 1994.
6. Rajaram S, Baylink DJ, Mohan S. IGFBPs in serum and other biological fluids. Endocr Rev 18:801-831, 1997.
7. Mohan S. IGF-binding proteins in bone cell regulation. Growth Regul 3:65-68, 1993.
8. Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804-1809, 1988.
9. Peacock M. Vitamin D receptor gene alleles and osteoporosis: A contrasting view. J Bone Miner Res 10:1294-1298, 1995.
10. Commuzzie AG, Blangero J, Mahaney MC, Haffner AM, Mitchell BD, Stern M, Mac Cluer JW. Genetic and environmental correlations among hormone levels and measures of body fat accumulation and topography. J Clin Endocrinol Metab 81:597-600, 1996.
11. Kurland E, Rackoff PJ, Adler RA, Bilezikian JP, Rogers J, Rosen CJ. Heritability of serum IGF-I and its relationship to bone density. Endocrine Society 80th annual meeting 1998; p99.
12. Boonen S, Lesaffre E, Dequeker J, Aersens J, Pelemans W, Bouillon R. Relationship between basal IGF-I and femoral bone density in women over 70 years. J Am Geriatr Soc 44:1301-1306, 1996.
13. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone 18:397-403, 1996.
14. Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, Baylink DJ. Circulating and skeletal IGF-I concentrations in two inbred strains of mice with different bone mineral densities. Bone 21:217-223, 1997.
15. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, Bilezikian JP. IGF-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 82:2799-2805, 1997.
16. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP. An association between serum IGF-I and a simple sequence repeat in the IGF-I gene: Implication for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-2290.
17. McKane W, Khosla S, Egan K, Riggs BL. Role of calcium intake in modulating age-related increases in PTH and bone resorption. J Clin Endocrinol Metab 81:1699-1703, 1996.
18. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delams PD. Markers of bone resorption predict hip fractures in elderly women: The EPIDOS prospective study. J Bone Miner Res 11:1531-1538, 1996.
19. Davis PY, Frazier CR, Shapiro JR, Fedarko NS. Age-related changes in effects of IGF-I on human osteoblast like cells. Biochem J 324:753-760, 1997.
20. Veldhuis JD, Iranmanesh A, Weltman A. Elements in the pathophysiology of diminished GH secretion in aging humans. Endocrine 7:41-48, 1997.
21. Boonen S, Aerssens J, Dequekeer J, Nicholson P, Chung X, Lovert G, Verhehe G, Bouillon R. Age-associated declines in human femoral neck and cortical and trabecular content of IGF-I. Calcif Tissue Int 61:173-178, 1997.
22. Zapf J, Schoenle E, Jagars G, Sand I, Grunwald J, Froesch ER. Inhibition of the action of nonsuppressible IGF activity on isolated rat fat cells by binding to its carrier protein. J Clin Invest 63:1077-1084, 1979.
23. Zapf J, Froesch E. IGFs/somatomedins: Structure, secretion, biological actions, and physiological roles. Horm Res 24:121-130, 1986.
24. Clemmons DR, Elgin RG, Han VKM, Casella SJ, D'Ercole AJ, Van Wyk JJ. Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin C-IGF I. J Clin Invest 77:1548-1556, 1986.
25. Elgin RG, Busby WHJ, Clemmons DR. An IGF binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA 84:3254-3258, 1987.
26. Blum WF, Jenne EW, Reppin F. IGF-I binding protein complex is a better mitogen than free IGF-I. Endocrinology 125:766-772, 1989.
27. Jones J, Gockerman A, Busby JW, Clemmons DR. Extracellular matrix contains IGFBP-5: Potentiation of the effects of IGF-I. J Cell Biol 121:679-687, 1993.
28. Roghani M, Hossenlopp P, LePage P, Ballard A, Binoux M. Isolation from human CSF of a new IGFBP with selective affinity for IGF-II. FEBS Lett 255:253-258, 1989.
29. Andress DL, Brinbaum RS. Human osteoblast-derived IGF binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 267:22467-22472, 1992.
30. Bautista C, Baylink DJ, Mohan S. Isolation of a novel IGF binding protein from human bone: A potential candidate for fixing IGF-II in human bone. Biochem Biophys Res Commun 176:756-763, 1991.
31. Hayden J, Mohan S, Baylink DJ. The IGF system and the coupling of formation to resorption. Bone 17:93S-98S, 1995.
32. Mohan S, Baylink DJ. Serum IGFBP-4 and IGFBP-5 in aging and age-associated diseases. Endocrine 7:87-91, 1997.
33. Mohan S, Farley JR, Baylink DJ. Age-related changes in IGFBP-4 and IGFBP-5 in human serum and bone: Implications for bone loss with aging. Progr Growth Factor Res 6:465-473, 1995.
34. Rosen CJ, Donahue LR, Hunter SJ, Kirshenbaum A, Kavookjian H, Holick MF, Mohan S, Baylink DJ. The 24/25 kDa serum IGFBP is increased in elderly women with hip and spine fractures. J Clin Endocrinol Metab 74:24-27, 1992.
35. Rosen T, Hannsson H, Granhed H, Szucs J, Bengtsson BA. Reduced bone mineral content in adults with GHD. Acta Endocrinol 129:201-206, 1993.
36. Beshyah SA, Kyd P, Thomas E, Fairny A, Johnston DG. The effects of prolonged GH replacement on bone turnover and bone mineral density in hypopituitary adults. Clin Endocrinol 42:249-254, 1995.
37. Marcus R. Skeletal effects of GH and IGF-I in adults. Endocrine 7:53-55, 1997.
38. Rudman D, Feller AG, Nelgrag HS. Effect of human GH in men over age 60. N Engl J Med 323:52-60, 1990.
39. Rudman D, Feller AG, Chohn L. Effect of rhGH on body composition in elderly men. Horm Res 36:73-81, 1991.
40. Papadakis MA, Grady D, Black D, Tremey MJ, Goding GAW, Grunfeld C. GH replacement in healthy older men improves body composition but not functional activity. Ann Intern Med 124:708-716, 1996.
41. Thompson JL, Butterfield GE, Marcus R. The effects of recombinant rhIGF-I and GH on body composition in elderly women. J Clin Endocrinol Metab 80:1845-1852, 1995.
42. Ghiron L, Thompson J, Halloway L, Hintz RL, Butterfield G, Hoffman A, Marcus R. Effects of rhIGF-I and GH on bone turnover in elderly women. J Bone Miner Res 10:1844-1877, 1995.
43. Holloway L, Kohlmeier L, Kent K, Marcus R. Skeletal effects of cyclic recombinant human GH and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol 82:1111-1117, 1997.
44. Maclean D, Kiel DP, Rosen CJ. Low dose rhGH for frail elders stimulates bone turnover in a dose-dependent manner. J Bone Miner Res 10(S1):458, 1995.
45. Ebeling P, Jones J, O'Fallon W, Janess C, Riggs BL. Short-term effects of recombinant IGF-I on bone turnover in normal women. J Clin Endocrinol Metab 77:1384-1387, 1993.
46. Wuster C, Blum W, Sclemilch S, Ranke M, Ziegler R. Decreased serum IGFs and IGFBP3 in osteoporosis. J Intern Med 234:249-255, 1993.
47. Bagi CM, Brommage R, DeLeon L, Adams S, Rosen D, Sommer A. Benefit of systemically administered rh IGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res 9:1301-1305, 1994.
48. Fowlkes J, Enghild J, Suzuki K, Nagase H. Matrix metalloproteinases degrade IGFBP-3 in dermal fibroblast cultures. J Biol Chem 269:25742-25746, 1994.
49. Conover C, Kiefer M. Regulation and biological effects of endogenous IGFBP-5 in human osteoblastic cells. J Clin Endocrinol Metab 76:1153-1159, 1993.
50. Kanzaki S, Hilliker S, Baylink DJ, Mohan S. Evidence that human bone cells in culture produce IGFBP-4 and IGFBP-5 proteases. Endocrinology 134:383-392, 1994.
51. Thraillkill K, Quarles LD, Nagase H, Suzuki K, Serra D, Fowlkes J. Characterization of IGFBP-5 degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136:3527-3533, 1995.
52. Hakeda Y, Kawaguchi H, Hurley M, Pilbeam C, Abreu C, Linkhart T, Mohan S, Kumegawa M, Raisz L. Intact IGFBP-5 associates with bone matrix and the soluble fragments of IGFBP-5 accumulated in culture medium of neonatal mouse calvariae by PTH and prostaglandin E2 treatment. J Cell Physiol 166:370-379, 1996.
53. Kudo Y, Iwashita M, Itatsu S, Iguchi S, Takeda Y. Regulation of IGFBP-4 protease activity by estrogen and PTH in SaOS-2 cells: Implications for the pathogenesis of postmenopausal osteoporosis. J Endocrinol 150:223-229, 1996.
54. Keene G, Parker M, Pryor G. Mortality and morbidity after hip fractures. BMJ 307:1248-1250, 1993.
55. Cook F, Rosen CJ, Vereault D, Steffens C, Kessenich CR, Greenspan S, Ziegler TR, Watts NB, Mohan S, Baylink DJ. Major changes in the circulatory IGF regulatory system after hip fracture surgery. J Bone Miner Res 11:S 327, 1996.
56. Schurch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P, Bonjour JP. Protein supplements increase serum IGF-I levels and attenuate proximal femur bone loss in patients with recent hip fractures. Ann Intern Med 1998;128:801-809.
57. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of growth releasing hormone 1-29 NH2 in age advanced men and women. J Clin Endocrinol Metab 82:1472-1479, 1997.